Figure S2


A
ELISA for anti-RBD or spike IgG, IgM, and IgA
HRP
anti-IgG
anti-IgM
anti-IgA
IgG
IgM
IgA
RBD or spike
B
RBD
SARS-CoV-2
SARS-CoV
MERS-CoV
O.D.
CR3022-IgG mAb (μg/mL)
C
IgG
IgM
IgA
R^2 = 0.81
p < 0.0001
R^2 = 0.79
p < 0.0001
R^2 = 0.90
p < 0.0001
anti-RBD Ab (U/mL)
anti-spike IgG (U/mL)
anti-spike IgM (U/mL)
anti-spike IgA (U/mL)
D
Severe respiratory syndrome CoVs RBD
SARS-CoV-2 (% ID)
SARS-CoV (73%)
MERS-CoV (17%)
Common cold CoVs RBD
HKU1 (20%)
NL63 (1.9%)
ACE2
spike
PDB ID: 6VSB
6VWI
2AJF
4L72
5GNB
3KBH
E
anti-RBD IgG O.D.
SARS1 RBD
MERS anti-RB
HKU1 RBD
NL63 RBD
SARS2 anti-RBD
SARS2 RBD
Healthy
COVID-19
F
SARS-CoV-2 spike
S1
S2
furin cleavage site
SS
RBD
TM
ER
full length
Δ18
1246
1273
GCCSCGSCCKFDEDDSEPVLKGVKLHYT
GCCSCGSCCK----------
ERRS
G
spike expression (MFI)
neg. ctrl
full length
Δ18
SARS-CoV-2
H
Titer (IU/mL)
VSV-G
full length
Δ18
SARS-CoV-2
I
Neutralization (%)
CR3022 mAb conc. (μg/mL)
J
No Serum
Serum 1:8,748
Serum 1:2,916
Serum 1:972
Serum 1:324
Serum 1:108
Serum 1:36
Serum 1:12
No Virus
Luminescence (RU)
Neutralization (%)
Luminescence
Neutralization
Serum Dilution
K
0.98% (12/1220)
54% (20/37)
Infection inhibition (NT50)
pre-pand
HIV/ART